Posted by SLS on December 15, 2006, at 7:14:23
In reply to Re: Riluzole - SLS, posted by rovers95 on December 13, 2006, at 21:19:30
> > Hi.
> >
> > Riluzole did not help me at all, but...
> >
> >
> > - Scott
> >
> >
> > ------------------------------------------
> >
> >
> > Biol Psychiatry. 2006 Dec 1;
> > [Epub ahead of print]
> >
> > Preliminary Evidence of Riluzole Efficacy in Antidepressant-Treated Patients with Residual Depressive Symptoms.
> >
> > * Sanacora G,
> > * Kendell SF,
> > * Levin Y,
> > * Simen AA,
> > * Fenton LR,
> > * Coric V,
> > * Krystal JH.
> >
> > Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
> >
> > BACKGROUND: Excessive glutamatergic neurotransmission may contribute to the pathophysiology of major depressive disorder (MDD). Recent evidence suggests that riluzole and other agents that target glutamate neurotransmission may show antidepressant activity. METHODS: Ten patients with treatment-resistant depression had riluzole added to their ongoing medication regimen for 6 weeks, followed by an optional 6-week continuation phase. Depression and anxiety severity were assessed using the Hamilton Depression Rating Scale (HDRS) and the Hamilton Anxiety Rating Scale (HARS). Linear mixed models were used to test for a linear trend in HDRS and HARS scores across time with treatment. RESULTS: Subjects' HDRS and HARS scores declined significantly following the initiation of riluzole augmentation therapy. The effect of riluzole was significant at the end of the first week of treatment and persisted for the 12-week duration of the study. CONCLUSIONS: These data suggest that riluzole augmentation produces antidepressant and anxiolytic effects in patients with treatment-resistant depression.
>
>
> What dosage did u try? Unable to find the dosage used in the above trial but am i right in thinking
> 50mg is the therapeutic dosage?!
I used 100mg. It made me feel somewhat worse after only 3 days. However, my case is a pretty poor representation of the average.
- Scott
-------------------------------------------------
Am J Psychiatry. 2004 Jan;161(1):171-4.An open-label trial of riluzole in patients with treatment-resistant major depression.
* Zarate CA Jr,
* Payne JL,
* Quiroz J,
* Sporn J,
* Denicoff KK,
* Luckenbaugh D,
* Charney DS,
* Manji HK.Laboratory of Molecular Pathophysiology and Experimental Therapeutics and the Pathophysiology Branch, Mood and Anxiety Disorders Program, NIMH, Department of Health and Human Services, NIH, Bethesda, MD 20892, USA. zaratec@intra.nimh.nih.gov
OBJECTIVE: This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression. METHOD: After a 1-week drug-free period, subjects 18 years or older with a diagnosis of recurrent major depression and a Montgomery-Asberg Depression Rating Scale score > or = 20 received riluzole monotherapy (100-200 mg/day) openly for 6 weeks. RESULTS: Nineteen treatment-resistant depressed patients, 53% of whom were classified as having stage 2 treatment resistance or greater, received riluzole at a mean dose of 169 mg/day. Significant improvement occurred during weeks 3 through 6 for all patients and weeks 2 through 6 for completers. CONCLUSIONS: Although preliminary, these results indicate that riluzole may have antidepressant properties in some patients.
poster:SLS
thread:711898
URL: http://www.dr-bob.org/babble/20061212/msgs/713870.html